JP2024537202A5 - - Google Patents
Info
- Publication number
- JP2024537202A5 JP2024537202A5 JP2024520992A JP2024520992A JP2024537202A5 JP 2024537202 A5 JP2024537202 A5 JP 2024537202A5 JP 2024520992 A JP2024520992 A JP 2024520992A JP 2024520992 A JP2024520992 A JP 2024520992A JP 2024537202 A5 JP2024537202 A5 JP 2024537202A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- biomarker
- therapeutic agent
- level
- ahp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252919P | 2021-10-06 | 2021-10-06 | |
| US63/252,919 | 2021-10-06 | ||
| PCT/US2022/077511 WO2023060064A1 (en) | 2021-10-06 | 2022-10-04 | Renal injury biomarkers as biomarkers for acute hepatic porphyria (ahp) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537202A JP2024537202A (ja) | 2024-10-10 |
| JP2024537202A5 true JP2024537202A5 (https=) | 2025-10-10 |
Family
ID=84331708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520992A Pending JP2024537202A (ja) | 2021-10-06 | 2022-10-04 | 急性肝性ポルフィリン症（ａｈｐ）のバイオマーカーとしての腎障害マーカー |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240360454A1 (https=) |
| EP (1) | EP4413378A1 (https=) |
| JP (1) | JP2024537202A (https=) |
| TW (1) | TW202329984A (https=) |
| WO (1) | WO2023060064A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118460654B (zh) * | 2024-07-10 | 2025-02-14 | 凯莱英医药集团（天津）股份有限公司 | 一种Givosiran的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| LT3052628T (lt) | 2013-10-04 | 2020-09-10 | Alnylam Pharmaceuticals, Inc. | Kompozicijos ir būdai alas1 geno raiškai nuslopinti |
| WO2021046329A1 (en) * | 2019-09-05 | 2021-03-11 | Octave Bioscience, Inc. | Biomarkers for predicting multiple sclerosis disease activity |
-
2022
- 2022-10-04 WO PCT/US2022/077511 patent/WO2023060064A1/en not_active Ceased
- 2022-10-04 JP JP2024520992A patent/JP2024537202A/ja active Pending
- 2022-10-04 EP EP22802413.9A patent/EP4413378A1/en active Pending
- 2022-10-04 TW TW111137690A patent/TW202329984A/zh unknown
-
2024
- 2024-04-01 US US18/623,281 patent/US20240360454A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7161554B2 (ja) | ミオスタチン阻害剤の使用および併用療法 | |
| US20210177823A1 (en) | Neuromodulating compositions and related therapeutic methods for the treatment of cancer | |
| McAdoo et al. | Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model | |
| Sanghera et al. | Pseudoprogression following chemoradiotherapy for glioblastoma multiforme | |
| US8133686B2 (en) | IL-8 as a biomarker for sunitinib resistance | |
| KR20170069262A (ko) | Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물 | |
| ES3052989T3 (en) | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 | |
| US20180113139A1 (en) | Methods and compositions for diagnosing and treating inflammatory bowel disorders | |
| CN114072503A (zh) | 载脂蛋白b拮抗剂 | |
| JP2024537202A5 (https=) | ||
| JP5918694B2 (ja) | 前立腺がんのマーカーとしてのホスホジエステラーゼ９ａ | |
| JP2025535729A (ja) | 神経変性疾患を評価及び治療するためのタンパク質マーカー | |
| TWI725532B (zh) | 治療牛皮癬之方法 | |
| JP2023542273A (ja) | Ａｍｌを処置するための治療、ならびにｒａｒａアゴニスト、低メチル化剤、およびｂｃｌ－２阻害剤の使用 | |
| CN119318706A (zh) | Nr3a作为蛋白靶点在筛选或制备预防和/或治疗抑郁样行为的药物中的应用 | |
| EP4306657A1 (en) | Composition for diagnosing pancreatic cancer | |
| JP2023526400A (ja) | 局所進行性又は転移性尿路上皮がんにおける免疫療法に対する感受性に関連する遺伝子変異量 | |
| Zhang et al. | Protease-activated receptors expression in gingiva in periodontal health and disease | |
| JP2007509604A (ja) | 薬剤誘発下痢の予測のためのバイオマーカー | |
| US20250019764A1 (en) | Methods for the prognosis and treatment of temporal lobe epilepsy | |
| CN114470196B (zh) | CCL3/CCR4中和抗体、NF-κB抑制剂在制备NEC治疗药物中的用途 | |
| CN114790233B (zh) | Optineurin在制备诊断和治疗肝硬化药物中的应用 | |
| CN111139299A (zh) | Josd2蛋白在制备治疗恶性肿瘤药物中的应用 | |
| Lund et al. | Selective Inhibition of Soluble Tumor Necrosis Factor Alters the Neuroinflammatory Response following Moderate Spinal Cord Injury in Mice. Biology 2023, 12, 845 | |
| Chen et al. | The Role and Mechanism of DcR2-Positive Failed Repair Cells in AKI: PO0412 |